Another Company Announces Positive Lupus Drug Data
Immunomedics has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug.
Immunomedics has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug.
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
Researchers identified three proteins, called Toll-Like Receptors (TLRs), that can cause the immune system to turn against the body.
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.
Copyright © 2024 | WordPress Theme by MH Themes